Progyny, Inc. PGNY
Nov 9, 2026, 1:38 PM EST
- YTD
- +39.23%
- 1 year
- +59.84%
- Market cap
- 2.64B
- Revenue (ttm)
- 1.34B
- Profit margin
- 6.80%
- EPS (ttm)
- 1.09
- Shares out
- 74.11M
- P/E ratio
- 32.83
- Forward P/E
- 14.72
- YTD return
- +39.23%
- 1-year return
- +59.84%
- Volume
- 627.18K
- Avg volume
- 1.11M
- Open
- 34.99
- Previous close
- 34.84
- Day's range
- 34.89 – 36.00
- 52-week range
- 16.10 – 36.00
- Beta
- 0.95
- Price target
- 34.42 (-3.7%)
- Earnings date
- Feb 25, 2027
5D +5.53 (+18.87%)
Key statistics
- Enterprise value
- 2.39B
- PEG ratio
- 0.00
- Price / sales
- 1.93
- Price / book
- 6.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 8.90%
- Free cash flow
- 199.57M
- Total cash
- 195.58M
- Total debt
- 21.73M
- Return on equity
- 18.69%
- Short % of float
- 9.39%
- 50-day average
- 27.27
- 200-day average
- 24.48
Analyst view
- Target (low)
- 30.00
- Target (mean)
- 34.42
- Target (high)
- 40.00
- Strong buy1
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.52535.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.3442 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.313 | 0.52 | +0.21 | +66.13% |
| Aug 6, 2026 | Jun 30, 2026 | 0.3348 | 0.36 | +0.03 | +7.53% |
| May 7, 2026 | Mar 31, 2026 | 0.256 | 0.30 | +0.04 | +17.19% |
| Feb 26, 2026 | Dec 31, 2025 | 0.147 | 0.15 | 0.00 | +2.04% |
| Nov 6, 2025 | Sep 30, 2025 | 0.39 | 0.16 | -0.23 | -58.97% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | Leerink Partners | main | Outperform | Outperform |
| Nov 5, 2026 | Wells Fargo | main | Overweight | Overweight |
| Nov 5, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Nov 5, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Sep 30, 2026 | Wells Fargo | init | — | Overweight |
| Sep 8, 2026 | Citizens | main | Market Outperform | Market Outperform |
About Progyny, Inc.
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Healthcare Plans
- Country
- United States
- Website
- progyny.com
News
Progyny (NASDAQ:PGNY) Reaches New 12-Month High After Earnings Beat 
Leerink Partners Maintains Outperform on Progyny, Raises Price Target to $38 
Wells Fargo Maintains Overweight on Progyny, Raises Price Target to $38 
Citizens Maintains Market Outperform on Progyny, Raises Price Target to $38 
Cantor Fitzgerald Maintains Overweight on Progyny, Raises Price Target to $35 
Progyny Q3 Earnings Call Highlights 
Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript 
Progyny (PGNY) Tops Q3 Earnings and Revenue Estimates 
Progyny Q3 2026 Earnings Call Transcript - Progyny Sees Q4 Adj EPS $0.53-$0.58 vs $0.34 Est; Sees Sales $344.700M-$364.700M vs $353.596M Est
Your note
Sign in to keep a note on PGNY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANEVSKI PETER | Chief Executive Officer | Stock Award(Grant) | Mar 1, 2026 | 816,834 |
| CLAPP GEOFFREY | Officer | Sale | Jun 1, 2026 | 60,647 |
| CUMMINGS MELISSA B | Chief Operating Officer | Sale | Jul 13, 2026 | 69,934 |
| DEAN LLOYD H | Director | Stock Award(Grant) | May 20, 2026 | 26,519 |
| HOLSTEIN ROGER C | Director | Stock Award(Grant) | May 20, 2026 | 28,729 |
| LIVINGSTON MARK S | Chief Financial Officer | Sale | Jun 3, 2026 | 74,688 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.12% | 11,599,921 | 404.14M | Jun 29, 2026 |
| FMR, LLC | 9.13% | 7,004,280 | 244.03M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.54% | 5,019,465 | 174.88M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.18% | 3,210,723 | 111.86M | Jun 29, 2026 |
| State Street Corporation | 3.94% | 3,022,859 | 105.32M | Jun 29, 2026 |
| Ameriprise Financial, Inc. | 3.60% | 2,763,514 | 96.28M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 4,566,776 | 159.11M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.92% | 2,242,829 | 78.14M | Jun 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.64% | 2,028,905 | 70.69M | Aug 30, 2026 |
| Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com | 2.53% | 1,940,666 | 67.61M | Jun 29, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.51% | 1,928,807 | 67.20M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.48% | 1,902,275 | 66.28M | Sep 29, 2026 |